Results 201 to 210 of about 2,285,787 (260)
Cancers, 2023 Breast cancer represents one of the most common tumor histologies. To date, based on the specific histotype, different therapeutic strategies, including immunotherapies, capable of prolonging survival are used. More recently, the astonishing results that
Ugo De Giorgi +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Imaging Chimeric Antigen Receptor (CAR) Activation
2020The chimeric antigen receptor (CAR) has been extensively exploited in cancer immunotherapy. In spite of the success of CAR T cells in clinical applications, the molecular mechanism underlying CAR-T cell activation remains unclear. Key questions remain: how are CARs activated by tumor antigens?
Kendra A, Libby, Xiaolei, Su
openaire +2 more sources
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma
NeuroMolecular Medicine, 2021Glioblastoma (GBM) are the most common and aggressive primary brain tumors in adults. Current mainstay treatments include surgery, chemotherapy, and radiation; however, these are ineffective. As a result, immunotherapy treatment strategies are being developed to harness the body's natural defense mechanisms against gliomas.
Lisa Feldman +2 more
openaire +2 more sources
Chimeric Antigen Receptor T-cells (CARs) in Cancer Treatment
Current Molecular Pharmacology, 2022Background: Cancer is one of the leading causes of death worldwide. Chemotherapy, radiation therapy, and stem cell transplantation were the main cancer treatment approaches for several years but due to their limited effectiveness, there was a constant search for new therapeutic approaches.
Wissam Zam, Amany Assaad
openaire +2 more sources
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma
2022Genetic modification of T cells to express chimeric antigen receptors (CARs) has yielded remarkable clinical outcomes and initiated a novel era for cancer immunotherapy. The impressive clinical responses seen in hematologic malignancies have led to the investigation of CAR T cells in solid tumors but attaining similar results has been challenging to ...
Amitesh, Verma, Sarwish, Rafiq
openaire +2 more sources
Chimeric Antigen Receptor (CAR) T Cells
2015Recent advances in cellular engineering techniques coupled with modern chimeric antigen receptors (CARs) now permit the efficient targeting and killing of malignant cells using patients’ own T cells. Freedom from MHC restriction by relying most commonly on single chain variable fragments of monoclonal antibodies for antigen recognition rather than T ...
Daniel W. Lee, Alan S. Wayne
openaire +1 more source
Chimeric Antigen Receptor (CAR) Redirected T Cells
2020Adoptive immunotherapy with chimeric antigen receptor (CAR) redirected T cells is a new therapeutic paradigm with a new class of therapeutic “drugs” producing complete and lasting remissions in patients with certain subtypes of so far refractory B cell malignancies.
Astrid Holzinger, Hinrich Abken
openaire +1 more source
In vivo chimeric antigen receptor (CAR)-T cell therapy
Nature Reviews Drug DiscoveryChimeric antigen receptor (CAR)-T cell therapy has transformed the outcomes of patients with haematological malignancies, yet its use is limited by labour-intensive manufacturing, constrained production capacity and variable clinical performance. In vivo CAR-T cell engineering, in which CAR-T cells are generated directly inside the patient's body ...
Adrian Bot +14 more
openaire +2 more sources
Chimeric antigen receptor (CAR) T therapy and cognitive functions
Journal of the Neurological Sciences, 2023Brendan Bryan Jen-Wei, Tan +4 more
openaire +2 more sources
Chimeric Antigen Receptor (CAR) T-Cell Therapy
JAMA Oncology, 2017John M, Pagel, Howard Jack, West
openaire +2 more sources